[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin 2018;68:7-30.

[2] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30.

[3] Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al., editors. Cancer of the lung and bronchus (invasive). In: SEER Cancer Statistics Review (CSR) 1975-2012. Bethesda, MD: National Cancer Institute; 2015.

[4] National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011;365:395- 409.

[5] Su S, Scott WJ, Allen MS. Patterns of Survival and Recurrence after Surgical Treatment of Early Stage Non-Small Cell Lung Carcinoma in the ACOSOG Z0030 (ALLIANCE) Trial. J Thorac Cardiovasc Surg 2014;147:747-53.

[6] Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of Stereotactic Ablative Radiotherapy for Centrally Located Early-Stage Lung Cancer. J Thorac Oncol 2011;6:2036-43.

[7] Sibley GS, Jamieson TA, Marks LB. Radiotherapy Alone for Medically Inoperable Stage I Non-Small-Cell Lung Cancer: The Duke Experience. Int J Radiat Oncol Biol Phys 1998;40:149-54.

[8] Zierhut D, Bettscheider C, Schubert K. Radiation Therapy of Stage I and II Non-Small Cell Lung Cancer (NSCLC). Lung Cancer 2001;34:S39-43.

[9] Qiao X, Tullgren O, Lax I. The Role of Radiotherapy in Treatment of Stage I Non-Small Cell Lung Cancer. Lung Cancer 2003;41:1-11.

[10] Blomgren H, Lax I, Göranson H. Radiosurgery for Tumors in the Body: Clinical Experience Using a New Method. J Radiosurg 1998;1:63-74.

[11] Nagata Y, Matsuo Y, Takayama K. Current Status of Stereotactic Body Radiotherapy for Lung Cancer. Int J Clin Oncol 2007;12:3-7.

[12] Song DY, Kavanagh BD, Benedict SH, Schefter T. Stereotactic Body Radiation Therapy. Rationale, Techniques, Applications, and Optimization. Oncology (Williston Park) 2004;18:1419-36.

[13] Ettinger DS, Wood DE, Aisner DL. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:504-35.

[14] Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and Locally Advanced NonSmall-Cell Lung Cancer (NSCLC): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and FollowUp. Ann Oncol 2017;28 Suppl 4:iv1-21.

[15] Videtic GM, Donington J, Giuliani M, Heinzerling J, Karas TZ, Kelsey CR, et al. Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 2017;7:295-301.

[16] Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non Small-Cell Lung Cancer Guideline. J Clin Oncol 2007;25:5506-18.

[17] National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology; 2020.

[18] Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of Stage I and II Non-Small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines. Chest 2013;143 Suppl 5:e278S-313S.

[19] Landreneau RJ, Normolle DP, Christie NA, Awais O, Wizorek JJ, Abbas G, et al. Recurrence and Survival Outcomes after Anatomic Segmentectomy Versus Lobectomy for Clinical Stage I Non-Small-Cell Lung Cancer: A Propensity-Matched Analysis. J Clin Oncol 2014;32:2449-55.

[20] Gonzalez-Rivas D, Paradela M, Fieira E, Velasco C. SingleIncision Video-Assisted Thoracoscopic Lobectomy: Initial Results. J Thorac Cardiovasc Surg 2012;143:745-7.

[21] Gonzalez-Rivas D. VATS Lobectomy: Surgical Evolution from Conventional VATS to Uniportal Approach. ScientificWorldJournal 2012;2012:780842.

[22] Vannucci F, Gonzalez-Rivas D. Is VATS Lobectomy Standard of Care for Operable Non-Small Cell Lung Cancer? Lung Cancer 2016;100:114-9.

[23] Palade E, Passlick B, Osei-Agyemang T, Günter J, Wiesemann S. Video-Assisted vs Open Mediastinal Lymphadenectomy for Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Randomized Trial. Eur J Cardiothorac Surg 2013;44:244-9; discussion 249.

[24] Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, et al. Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient with N0 or N1 (Less than Hilar) Non-Small Cell Carcinoma: Results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011;141:662-70.

[25] Hung WT, Cheng YJ, Chen JS. Non Intubated Thoracoscopic Surgery for Early-Stage Non-Small Cell Lung Cancer. Gen Thorac Cardiovasc Surg 2020;68:733-9.

[26] Kneuertz PJ, D’Souza DM, Richardson M, Abdel-Rasoul M, Moffatt-Bruce SD, Merritt RE. LongTerm Oncologic Outcomes after Robotic Lobectomy for Early-stage Non-Small-Cell Lung Cancer Versus Videoassisted Thoracoscopic and Open Thoracotomy Approach. Clin Lung Cancer 2020;21:214-24.e2.

[27] Ito H, Suzuki K, Mizutani T, Aokage K, Wakabayashi M, Fukuda H, et al. Long-Term Survival Outcome after Lobectomy in Patients with Clinical T1 N0 Lung Cancer. J ThoracCardiovasc Surg 2020;161:281-90.

[28] Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafi AS, et al. Perioperative Mortality and Morbidity after Sublobar Versus Lobar Resection for Early-Stage Non-Small-Cell Lung Cancer: Post-Hoc Analysis of an International, Randomised, Phase 3 Trial (CALGB/Alliance 140503). Lancet Respir Med 2018;6:915-24.

[29] Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.

[30] Pathak R, Hoag JR, Goldberg SB, Monsalve AF, Resio B, Boffa DJ. Refining the Role of Adjuvant Chemotherapy in Stage IB and IIA NSCLC. J Clin Oncol 2019;37S:8519.

[31] Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, et al. Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected NonSmall-Cell Lung Cancer. N Engl J Med 2004;350:351-60.

[32] Scagliotti GV, Fossati R, Torri V, Crinò L, Giaccone G, Silvano G, et al. Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer. J Natl Cancer Inst 2003;95:1453-61.

[33] Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, et al. Adjuvant Vinorelbine Plus Cisplatin Versus Observation in Patients with Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (Adjuvant Navelbine International Trialist Association ANITA): A Randomised Controlled Trial. Lancet Oncol 2006;7:719-27.

[34] Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine Plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer. N Engl J Med 2005;352:2589-97.

[35] Strauss GM, Herndon J, Maddaus MA, Johnstone DW, Johnson EA, Watson DM, et al. Randomized Clinical Trial of Adjuvant Chemotherapy with Paclitaxel and Carboplatin Following Resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 (Abstract). Proc Am Soc Clin Oncol 2004;23:621s.

[36] Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant Paclitaxel Plus Carboplatin Compared with Observation in stage IB NonSmall-Cell Lung Cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-51.

[37] Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, et al. Adjuvant Chemotherapy for Resected Early-Stage Non-Small Cell Lung Cancer. Cochrane Database Syst Rev 2015;3:CD011430.

[38] Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, et al. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol 2017;5:2960-74.

[39] Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, et al. Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared with Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10. J Clin Oncol 2010;28:29-34.

[40] KreuterM, Vansteenkiste J, Fischer JR, Eberhardt WE, Zabeck H, Kollmeier J, et al. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of EarlyStage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). J Thorac Oncol 2016;11:85-93.

[41] Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III Study Comparing Cisplatin Plus Gemcitabine with Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients with Advanced-Stage Non-Small-Cell Lung Cancer. J Clin Oncol 2008;26:3543-51.

[42] Morgensztern D, Du L, Waqar SN, Patel A, Samson P, Devarakonda S, et al. Adjuvant Chemotherapy for Patients with T2N0M0 Non-Small-Cell Lung Cancer (NSCLC). J Thorac Oncol 2016;11:1729-35.

[43] Bradbury P, Sivajohanathan D, Chan A, Kulkarni S, Ung Y, Ellis PM. Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review. Clin Lung Cancer 2017;18:259-73.

[44] Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, et al. Adjuvant Chemotherapy with or Without Bevacizumab in Patients with Resected Non-Small-Cell Lung Cancer (E1505): An Open-Label, Multicentre, Randomised, Phase 3 Trial. Lancet Oncol 2017;18:1610-23.

[45] Huang O, Li J, Sun Y, Wang R, Cheng X, Chen H. Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-Small Cell Lung Cancer by a Meta-Analysis. Chest 2016;149:1384-92.

[46] Tada H, Takeda K, Nakagawa K, Okamoto I, Mitsudomi T, Sugio YI, et al. Vinorelbine Plus Cisplatin Versus Gefitinib in Resected Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation (WJOG6410L). J Clin Oncol 2012;30:TPS7110.

[47] Forde PM, Chaft JE, Pardoll DM. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 2018;378:1976-86.

[48] Postoperative Radiotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis of Individual Patient Data from Nine Randomised Controlled Trials. PORT Meta-analysis Trialists Group. Lancet 1998;352:257-63.

[49] Trodella L, Granone P, Valente S, Valentini V, Balducci M, Mantini G, et al. Adjuvant Radiotherapy in Non-Small Cell Lung Cancer with Pathological Stage I: Definitive Results of a Phase III Randomized Trial. Radiother Oncol 2002;62:11-9.

[50] Douillard JY, Rosell R, de Lena M, Riggi M, Hurteloup P, Mahe MA, et al. Impact of Postoperative Radiation Therapy on Survival in Patients with Complete Resection and Stage I, II, or III A Non-Small-Cell Lung Cancer Treated with Adjuvant Chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 2008;72:695-701.

[51] Francis S, Orton A, Stoddard G, Tao R, Hitchcock YJ, Akerley W, et al. Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer. J Clin Oncol 2018;36:333-41.

[52] Ramroth J, Cutter DJ, Darby SC, Higgins GS, McGale P, Partridge M, et al. Dose and Fractionation in Radiation Therapy of Curative Intent for Non-Small Cell Lung Cancer: Meta-Analysis of Randomized Trials. Int J Radiat Oncol Biol Phys 2016;96:736-47.

[53] Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-Small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese MultiInstitutional Study. J Thorac Oncol 2007;2 Suppl 3:S94- 100.

[54] Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, et al. Stereotactic Ablative Radiotherapy Versus Standard Radiotherapy in Stage 1 Non-Small-Cell Lung Cancer (TROG 09.02 CHISEL): A Phase 3, Open-Label, Randomised Controlled Trial. Lancet Oncol 2019;20:494- 503.

[55] Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, et al. Extracranial Stereotactic Radioablation: Results of a Phase I Study in Medically Inoperable Stage I Non-Small Cell Lung Cancer. Chest 2003;124:1946-55.

[56] Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys 2015;93:989-96.

[57] Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, et al. Promising Clinical Outcome of Stereotactic Body Radiation Therapy for Patients with Inoperable Stage I/II Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2006;66:117-25.

[58] Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy. J Clin Oncol 2009;27:3290-6.

[59] Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. JAMA 2010;303:1070-6.

[60] Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, et al. 7-Year Follow-Up after Stereotactic Ablative Radiotherapy for Patients with Stage I Non-Small Cell Lung Cancer: Results of a Phase 2 Clinical Trial. Cancer 2017;123:3031-9.

[61] Chen H, Laba JM, Boldt RG, Goodman CD, Palma DA, Senan S, et al. Stereotactic Ablative Radiation Therapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score Studies. Int J Radiat Oncol Biol Phys 2018;101:186-94.

[62] Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic Ablative Radiotherapy Versus Lobectomy for Operable Stage I Non-Small-Cell Lung Cancer: A Pooled Analysis of Two Randomised Trials. Lancet Oncol 2015;16:630-7.

[63] Anon. A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC). Available from: https://clinicaltrials. gov/ct2/show/NCT02468024.

[64] Anon. Veterans Affairs Lung Cancer or Stereotactic Radiotherapy (VALOR). Available from: https:// clinicaltrials.gov/ct2/show/NCT02984761.

[65] Snee MP, McParland L, Collinson F, Lowe CM, Striha A, Baldwin DR, et al. The SABRTooth Feasibility Trial Protocol: A Study to Determine the Feasibility and Acceptability of Conducting a Phase III Randomised Controlled Trial Comparing Stereotactic Ablative Radiotherapy (SABR) with Surgery in Patients with Peripheral Stage I Non-Small Cell Lung Cancer (NSCLC) Considered to be at Higher Risk of Complications from Surgical Resection. Pilot Feasibility Stud 2016;2:5.

[66] Bezjak A, Paulus R, Gaspar LE, Timmerman R, Straube B, Ryan WF, et al. Primary Study Endpoint Analysis for NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located NonSmall Cell Lung Cancer (NSCLC). Int J Radiat Biol Phys 2016;94:5-6.

[67] Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive Toxicity when Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer. J Clin Oncol 2006;24:4833-9.

[68] Song SY, Choi W, Shin SS, Lee SW, Ahn SD, Kim JH, et al. Fractionated Stereotactic Body Radiation Therapy for Medically Inoperable Stage I Lung Cancer Adjacent to Central Large Bronchus. Lung Cancer 2009;66:89-93.

[69] Modh A, Rimner A, Williams E, Foster A, Shah M, Shi W, et al. Local Control and Toxicity in a Large Cohort of Central Lung Tumors Treated with Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2014;90:1168-76.

[70] Haseltine JM, Rimner A, Gelblum DY, Modh A, Rosenzweig KE, Jackson A, et al. Fatal Complications after Stereotactic Body Radiation Therapy for Central Lung Tumors Abutting the Proximal Bronchial Tree. Pract Radiat Oncol 2016;6:e27-33.

[71] Chang JK, Li QQ, Xu QY, Allen PK, Rebueno N, Gomez DR, et al. Stereotactic Ablative Radiation Therapy for Centrally Located Early Stage or Isolated Parenchymal Recurrences of Non-Small Cell Lung Cancer: How to Fly in a “No Fly Zone”. Int J Radiation Oncol Biol Phys 2014;88:1120-8.

[72] Corradetti MN, Haas AR, Rengan R. Central-Airway Necrosis after Stereotactic Body-Radiation Therapy. N Engl J Med 2012;366:2327-9.

[73] Stam B, Kwint M, Guckenberger M, Mantel F, Hope A, Giuliani M, et al. Subgroup Survival Analysis in Stage I-II NSCLC Patients with a Central Tumor Partly Treated with Risk-Adapted SBRT. Int J Radiat Oncol Biol Phys 2018;103:132-41.

[74] Tekatli H, Haasbeek N, Dahele M, de Haan P, Verbakel W, Bongers E, et al. Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with “Ultracentral” Non-Small Cell Lung Cancer. J Thorac Oncol 2016;11:1081-9.

[75] Chaudhuri AA, Tang C, Binkley MS, Jin M, Wynne JF, von Eiven R, et al. Stereotactic Ablative Radiotherapy (SABR) for Treatment of Central and Ultra-Central Lung Tumors. Lung Cancer 2015;89:50-6.

[76] Senthi S, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of Stereotactic Ablative Radiotherapy for Central Lung Tumours: A Systematic Review. Radiother Oncol 2013;106:276-82.

[77] Chang JH, Poon I, Erler D, Zhang L, Cheung P. The Safety and Effectiveness of Stereotectic Body Radiotherapy for Central Versus Ultracentral Lung Tumors. Radiother Oncol 2018;129:277-83.

[78] Rim CH, Kim Y, Kim CY, Yoon WS, Yang DS. Is Stereoctactic Body Radiotherapy for Ultra-Central Lung Tumor a Feasible Option? A Systemic Review and MetaAnalysis. Int J Radiation Oncol Biol Phys 2019;95:329-37.

[79] Murrell DH, Laba JM, Erickson A, Millman B, Palma DA, Louie AV. Stereotactic Ablative Radiotherapy for UltraCentral Lung Tumors: Prioritize Target Coverage or Organs at Risk? Radiat Oncol 2018;13:57.

[80] Palma D, Daly M, Urbanic J, Giuliani M. Stereotactic Radiation for Ultra-Central Lung Tumors: Good Idea, or Ultra-Risky? Int J Radiat Oncol Biol Phys 2019;103:788-91.

[81] Abedahr S, Colette S, Shash E, Lambretch M, Le Pechoux C, Faivre-Finn C, et al. LungTech, an EORTC Phase II Trial of Stereotactic Body Radiotherapy for Centrally Located Lung Tumors: A Clinical Perspective. Br J Radiol 2015;88:20150036.

[82] Lindberg K, Bergström P, Brustugun OT, Engelholm S, Grozman V, Hoyer M. The Nordic HILUS-Trial-First Report of a Phase II Trial OS SBRT of Centrally Located Lung. J Thorac Oncol 2017;12:S340.

[83] Giuliani M, Mathew A, Bahig H, Bratman S, Filion E, Glick D, et al. SUNSET: Stereotactic Radiation for Ultracentral NSCLC-a Safety and Efficacy Trial. Clin Lung Cancer 2018;19:e529-32.

[84] Foster CC, Rusthoven CG, Sher DJ, Feldman L,Pasquinelli M, Spiotto MT, et al. Adjuvant Chemotherapy Following Stereotactic Body Radiotherapy for Early Stage Non-Small-Cell Lung Cancer is Associated with Lower Overall: A National Cancer Database Analysis. Lung Cancer 2019;130:162-8.

[85] Welsh JW, Tang C, de Groot P, Naing A, Raju U, Shaaban S, et al. Phase 2 5-Arm Trial of Ipilimumab Plus Lung or Liver Stereotactic Radiation for Patients with Advanced Malignancies. Int J Radiat Oncol 2017;99:1315.

[86] Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, et al. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients with Advanced Solid Tumors. J Clin Oncol 2018;36:1611-8.

[87] Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017;377:1919-29.

[88] Chen H, Senan S, Nossent EJ, Boldt RG, Warner A, Palma DA, et al. Treatment-Related Toxicity in Patients with Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review. Int J Radiat Oncol Biol Phys 2017;98:622-31.

[89] Palussiere J, Catena V, Buy X. Percutaneous Thermal Ablation of Lung Tumors Radiofrequency, Microwave and Cryotherapy: Where are we Going? Diagn Interv Imaging 2017;98:619-25.

[90] Donington J, Ferguson M, Mazzone P, Handy J Jr., Schuchert M, Fernando H, et al. American College of Chest Physicians and Society of Thoracic Surgeons Consensus Statement for Evaluation and Management for High-Risk Patients with Stage I Non-Small Cell Lung Cancer. Chest 2012;142:1620-35.

[91] Li G, Xue M, Chen W, Yi S. Efficacy and Safety of Radiofrequency Ablation for Lung Cancers: A Systematic Review and Meta-Analysis. Eur J Radiol 2018;100:92-8.

[92] Koizumi T, Tsushima K, Tanabe T, Agatsuma T, Yokoyama T, Ito M, et al. Bronchoscopy-Guided Cooled Radiofrequency Ablation as a Novel Intervention Therapy for Peripheral Lung Cancer. Respiration 2015;90:47-55.

[93] Steinfort DP, Herth FJ. Bronchoscopic Treatments for Early-Stage Peripheral Lung Cancer: Are we Ready for Prime Time? Respirology 2020;25:944-52.